HeartSciences Stock Rated “Strong Buy” by Analysts

The Company is offering, on a “best efforts’ basis, up to 4,285,714 Units, each Unit consisting of one (1) share of  Series D Convertible Preferred Stock and one (1) warrant to purchase common stock. The Units will be sold at an offering price of $3.50 per Unit. The warrants are exercisable at a price of $5.00 for one (1) share of Common Stock.

All of HeartSciences’ regulatory filings, including financial reports, can be found here:

The Units will be sold at an offering price of $3.50 per Unit, for a maximum offering amount of  $15,000,000.

Investing in startups is risky and there is no guarantee you will get a return on your investment. However, the fact that our common stock is listed on Nasdaq (Nasdaq: HSCS) opens up an opportunity for you to convert your preferred shares into common stock providing an exit in cash (if you choose to sell the common stock) or desire to hold a more liquid asset. If the value of our Company grows, then you have a higher potential of making a profit on your investment.You are investing in a pre-revenue company selling an emerging technology. Success will be measured in progress towards commercialization and growing revenue and profitability.

Shares will be issued through the transfer agent, Equiniti Trust Company, LLC after the investment funds clear.

No, costs are the same, regardless of how you invest.

The Company expects to achieve many milestones in 2025, including FDA clearance which would be expected to see an increase in our share price. We are already listed on Nasdaq so there is the ability to buy and sell our Common Stock. Additionally, the warrants offer the ability to buy further shares at a fixed price.

The FDA has already created a new clinical pathway specifically for AI-ECG, the American Medical Association issued new reimbursement codes and in early 2025 Medicare agreed to start paying for use of AI-ECG. Mayo Clinic is expected to be one of the early adopters and has already used the reimbursement code for AI-ECG tens of thousands of times.

We are at the beginning of what is expected to be a new era for an ECG and its clinical capabilities and we expect many new opportunities. We would expect to bring a portfolio of valuable algorithms into clinical practice and have plans to roll-out further upgrades for both the MyoVista wavECG device and MyoVista Insights cloud-platform. We also have a number of international opportunities and relationships.

The big companies tend to focus on maximizing sales of existing products rather than innovation of new ones. Additionally, the data required to develop new algorithms is held by clinical institutions rather than companies and is a barrier to entry and why our clinical collaborations and partnerships in this field are valuable.

Proceeds from this offering will be used to fund the Company achieving regulatory clearances for its products as well as on-going R&D and clinical activities, sales and marketing and general corporate purposes.

Based on the $3.50 conversion price the pre-money valuation is $4 million.

Your support and commitment will help HeartSciences shape the future of heart healthcare and early detection of heart disease.

If we are able to raise the full amount it is anticipated that this will allow us to get our first products to market. We would expect to need additional capital at that time to market and sell the product. 

We are a Nasdaq listed company. Investors can convert their Preferred Stock to Common Stock and are free to trade it at any time. We also anticipate that as we get into sales the Company may well be attractive for acquisition by a larger medical devices company.

We are a medical technology company focused on making the ECG (also known as an EKG) significantly more clinically valuable so that it can detect heart disease earlier. The ECG is one of the most ubiquitous medical tests in the world and performed millions of times a week across healthcare settings including in hospitals, doctor’s offices, other healthcare providers, and retail and screening clinics.

We are a listed company with over 3,000 holders of our common stock.

We do not intend to pay dividends in the near future.

HeartSciences is focussed on making the ECG (also known as an EKG) far more clinically valuable so that so that it can detect heart disease earlier. We are developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting worldwide, either via our MyoVista Insights™ cloud-platform using one of the millions of ECG devices currently in clinical use or via our MyoVista® wavECG™ Device.

Southlake, Texas

15

In addition to the USA, we already have established clinical relationships in Europe, Australia and India and have distributors appointed in those markets.

Yes we already have established clinical relationships in Europe, Australia and India and have distributors appointed in those markets. We intend to market our products in those areas regulatory clearances.

Our business model is based on valuable recurring revenues charging a fee for single use supplies, use of algorithms and/or a SaaS subscription which are all at high margin. We expect revenue to start in 2026 and increase substantially as products are adopted and there is an installed user base. Today, more than 100 million ECG tests are performed in the US alone and accordingly, we expect to become profitable much earlier than most medical device companies.

Yes, that is one of several potential revenue streams.

43 patents.

See #18 above

The traditional ECG market is dominated by large medical device manufacturers like GE Healthcare. However, traditional ECGs are decades old technology. AI-ECG is a fast emerging new field with a handful of early stage companies. We have been around longer and have significantly greater experience and relationships in this field than most other companies. We are the only company developing holistic device and cloud-native device agnostic AI-ECG solutions which will enable us to deliver AI-ECG solutions across a wide range of healthcare settings, from large hospital systems to simple nurse-led mobile testing services

The ECG is one of the most ubiquitous medical tests in the world and performed millions of times a week across healthcare settings including in hospitals, doctor’s offices, other healthcare providers, and retail and screening clinics.

We are already partnering with several healthcare institutions and overtime see enormous opportunities for partnering with other companies. Either alternative/ telehealth ECG hardware (such as the Apple watch) or the MyoVista Insights platform providing an AI-ECG marketplace to host third party algorithms.

The development of AI-ECG algorithms requires access to significant health care data. We have collaborated with many healthcare institutions such in the US, the UK, Denmark and Australia and licenced considerable IP from Mount Sinai, New York which is one of the world’s leading cardiology healthcare institutions.